Send to

Choose Destination
Respir Med Case Rep. 2017 Jul 14;22:101-105. doi: 10.1016/j.rmcr.2017.07.004. eCollection 2017.

Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases.

Author information

Pulmonary Department-Oncology Unit, "Theageneio" Anticancer Hospital, Thessaloniki, Greece.
Pulmonary Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra Hospital, Athens, Greece.
Microdiagnostics, Pathology Private Center, Thessaloniki, Greece.
Surgery Department, "Interbalkan" European Medical Center, Thessaloniki, Greece.
Pharmacology-Clinical Pharmacology, Department of Clinical, Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Department of Respiratory and Critical Care Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China.
Sana Clinic Group Franken, Department of Cardiology / Pulmonology / Intensive Care / Nephrology, "Hof" Clinics, University of Erlangen, Hof, Germany.


In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients.


Adenocarcinoma; Colitis; Immunotherapy; NSCLC; Nivolumab; Pericarditis; Pneumonitis

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center